This article is more than 5 years old. Information may no longer be current.

Alcon reports 12.3% increase in second quarter sales

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HUNENBERG, Switzerland — Global sales for Alcon totaled $1.47 billion during the second quarter of this year, a 12.3% increase over global sales for the second quarter 2006, the company announced in a press release.

Net earnings for the second quarter fell 3.7% to $448.4 million, or $1.48 per diluted share, compared with $465.6 million, or $1.50 per diluted share, for the second quarter of last year.

Compared with the second quarter of 2006, pharmaceutical sales increased 13.3% to $633.8 million. Glaucoma product sales increased 13.7% and were led by sales growth for Travatan (travoprost) products internationally and by sales of Azopt (brinzolamide). Specifically, Travatan product sales increased 24.6%.

Infection and inflammation product sales increased 5.7%, while sales of allergy products increased 16.6%, which were driven by successful product launches in Japan and the United States.

Surgical product sales increased 11.5% to $632.4 million. Sales of IOLs increased 13.7% to $233.7 million, with a 9.6% increase in AcrySof sales. In particular, premium IOL sales increased 24%, driven by international sales of AcrySof ReSTOR lenses and U.S. sales of AcrySof Toric lenses, according to the release.

Cataract and vitreoretinal product sales increased 11.7%. However, refractive revenue declined 28.1% for the quarter, which the company primarily attributed to decreases in U.S. per procedure technology fees.

Consumer eye care sales increased 11.6% to $205.3 million, led by a 15.5% rise in sales of contact lens disinfectants.

For the full year, Alcon expects total sales between $5.475 billion $5.55 billion, for adjusted diluted earnings per share between $5.20 and $5.30, according to the release.